TELO · Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals Inc (TELO)
What's happening
- TELO is down 8.70% today, trading at $1.05. — Live quote
- Volume today (305) is well below its 3-month average of 103,650. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.28 actual vs. $-0.07 estimated (-292.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.8M | $42.3M | $51.1M | $37.7M | $101.5M |
| P/E | -0.31 | -4.53 | -3.56 | -2.58 | -6.42 |
| Price/Book | 0.55 | 8.52 | 7.32 | 78.40 | -630.13 |
| ROE | -176.51% | -188.28% | -205.50% | -3040.06% | 9816.06% |
| ROA | -165.58% | -161.38% | -193.77% | -1763.41% | -3219.58% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -39.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TELO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | — | — | — | — | $2.2M | — | — | $1.9M |
| Net income | -$1.7M | -$990.9K | -$1.1M | -$5.1M | -$2.2M | -$6.0M | -$1.4M | -$6.3M |
| EPS (diluted) | $-0.79 | $-0.03 | $-0.03 | $-0.17 | $-0.07 | $-0.20 | $0.05 | $-0.23 |
| EPS (basic) | $-0.79 | $-0.03 | $-0.03 | $-0.17 | $-0.07 | $-0.20 | $0.05 | $-0.23 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $5.4M | $5.8M | $7.3M | $7.4M | $829.6K | $491.2K | $1.3M | $1.0M |
| Total liabilities | $332.4K | $827.3K | $1.4M | $422.8K | $348.4K | $652.3K | $681.0K | $599.9K |
| Stockholders' equity | $5.0M | $5.0M | $5.9M | $7.0M | $481.2K | -$161.1K | $643.0K | $442.1K |
| Total current assets | $5.4M | $5.8M | $7.3M | $7.4M | $829.6K | $491.2K | $1.3M | $1.0M |
| Total current liabilities | $332.4K | $827.3K | $1.4M | $422.8K | $348.4K | $652.3K | $681.0K | $599.9K |
| Cash & equivalents | — | — | — | — | $754.3K | $403.0K | $1.3M | — |
| Other current liabilities | — | $344.8K | $318.2K | $93.4K | $93.4K | $93.4K | $93.4K | — |
| Retained earnings | -$43.7M | -$42.0M | -$41.0M | -$38.9M | -$37.8M | -$32.8M | -$30.6M | -$27.7M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.0M | -$1.8M | -$1.2M | -$927.3K | -$696.4K | -$863.1K | -$605.8K | -$1.0M |
| Financing cash flow | $622.1K | $47.4K | $1.2M | $7.5M | $1.0M | — | $1.0M | -$46.9K |
| Share-based compensation | $198.7K | $39.8K | -$7.9K | -$741.9K | $4.7M | $1.4M | $2.1M | $4.8M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Net income | -$10.4M | -$16.5M | -$13.1M | -$854.1K |
| EPS (diluted) | $-0.33 | $-0.56 | $0.48 | $-0.03 |
| EPS (basic) | $-0.33 | $-0.56 | $0.48 | $-0.03 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $7.3M | $1.3M | $4.8M | $48.7K | — |
| Total liabilities | $1.4M | $681.0K | $1.3M | $986.0K | — |
| Stockholders' equity | $5.9M | $643.0K | $3.4M | -$937.3K | -$138.1K |
| Total current assets | $7.3M | $1.3M | $435.2K | $48.7K | — |
| Total current liabilities | $1.4M | $681.0K | $1.3M | $986.0K | — |
| Other current liabilities | $318.2K | $93.4K | $527.4K | — | — |
| Retained earnings | -$41.0M | -$30.6M | -$14.1M | -$992.3K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Operating cash flow | -$3.7M | -$5.1M | -$3.9M | -$468.7K |
| Financing cash flow | $9.7M | $6.3M | $3.9M | $470.1K |
| Share-based compensation | $5.3M | $6.9M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TELO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 17 most recent filings · covers 2024-02-13 to 2026-04-22
Recent transactions
- Most recent: Aminov Erez (CEO and Chairman) — Other acquisition/disposition of 7,319,710 shares on 2026-04-22.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Aminov Erez | CEO and Chairman | Other acquisition/disposition | 2026-04-22 | 7,319,710 |
| Bay Shore Trust | Reporting person | Open market purchase | 2024-02-13 | 49,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-04-22 | Aminov Erez | CEO and Chairman | Other acquisition/disposition | 7,319,710 | $1.37 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:10 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-06 | 8-K | 2026-10-05 | View on SEC.gov → |
| 2026-09-17 | 8-K | 2026-09-17 | View on SEC.gov → |
| 2026-09-16 | 8-K | 2026-09-11 | View on SEC.gov → |
| 2026-09-14 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-07-27 | 4 | 2026-04-16 | View on SEC.gov → |
| 2026-07-27 | 4 | 2026-04-16 | View on SEC.gov → |
| 2026-07-27 | 4 | 2026-04-16 | View on SEC.gov → |
| 2026-06-15 | 8-K | 2026-06-15 | View on SEC.gov → |
| 2026-06-08 | 8-K | 2026-06-03 | View on SEC.gov → |
| 2026-05-22 | 4 | 2026-05-21 | View on SEC.gov → |
Recent news
Headlines about TELO (Telomir Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Yahoo Finance · 2026-10-06 -
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
Yahoo Finance · 2026-09-17 -
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
Yahoo Finance · 2026-09-14 -
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
Yahoo Finance · 2026-08-10 -
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Yahoo Finance · 2026-06-15 -
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
Yahoo Finance · 2026-05-20 -
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
Yahoo Finance · 2026-04-30 -
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
Yahoo Finance · 2026-04-24
No headlines in this category right now — try “All”.